1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Cerus Corporation

Cerus Corporation

CERS
Cerus CorporationUS flagNASDAQ Global Market
3.02
USD
-0.10
- -
605.11MMarket Cap
Cerus Corporation
CERS
(NASDAQ Global Market)

Recent

price

3.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.54
0.64
0.67
0.59
0.49
0.36
0.37
0.4
0.46
0.53
0.56
0.76
0.92
0.87
0.98
1.08
1.13
Revenue per Share
-0.42
-0.35
-0.29
-0.64
-0.52
-0.58
-0.62
-0.56
-0.44
-0.51
-0.37
-0.32
-0.24
-0.21
-0.11
-0.08
-0.05
Basic EPS, GAAP
-0.4
-0.33
-0.26
-0.4
-0.53
-0.53
-0.53
-0.48
-0.24
-0.47
-0.26
-0.2
-0.15
-0.24
0.06
0.03
0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-10.59
-9.24
-8.43
-7.45
-7.25
-6.22
-6.49
-6.66
-5.91
-6.08
-5.55
-5.63
-5.7
-5.79
-5.77
-5.67
-5.63
Book Value per Share
0.27
0.12
0.3
0.59
0.52
0.96
0.55
0.34
0.63
0.4
0.63
0.49
0.38
0.29
0.3
0.33
0.35
Tangible Book Value per Share
40
48
55
68
75
96
102
108
132
140
164
171
177
180
185
191
192
Basic Weighted Avg Shares
22
31
37
40
36
34
37
44
61
75
92
131
162
156
180
206
217
Sales/Revenue/Turnover
-72.78
-52.04
-47.15
-71.36
-122.21
-178.46
-164.85
-132.05
-90.28
-88.72
-63.46
-37.4
-21.03
-16.84
-7.89
-4.21
-1.47
Operating Margin (%)
1
1
1
1
1
2
2
2
1
2
3
3
3
3
2
1
2
Depreciation Expense
-17
-17
-16
-43
-39
-56
-63
-61
-58
-71
-60
-54
-43
-37
-21
-16
-10
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
130.77
Effective Tax Rate (%)
-78.01
-55.49
-43.38
-109.28
-106.42
-163.25
-169.18
-139.06
-94.51
-95.44
-65.12
-41.55
-26.4
-23.98
-11.6
-7.58
-4.41
Profit Margin (%)
22
19
18
39
46
109
67
67
94
78
123
109
53
77
88
74
68
Working Capital
3
5
3
- -
10
17
12
30
22
58
56
71
29
74
77
51
42
LT Debt
24
18
19
43
42
95
58
39
85
57
104
86
69
53
57
65
68
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-51.44
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
39
46
56
LT Borrowings
49
41
32
LT Finance Leases
11
10
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
192
192
200
Market Capitalization
300
393
350

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
167
174
175
Cash, Cash Equivalents & STI
79
83
80
Accounts Receivable, Net
30
30
29
Inventories
53
56
61
Total Current Liabilities
88
101
107
Payables & Accruals
33
35
38
ST Debt
39
46
56
Deferred Revenue
2
1
2

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.6%
-7.77%
14.18%
Free Cash Flow
-12.3%
-31.71%
-57.42%
Net Income, GAAP
-10.06%
-22.47%
-25.29%
Sales/Revenue/Turnover
20.36%
18.46%
14.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38
45
46
51
180
2025
43
52
53
58
206
2026
54
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.03
-0.02
-0.01
-0.11
2025
-0.04
-0.03
- -
-0.01
-0.08
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Enovis Corporation (0I1B.L)
NewCardio, Inc. (NWCI)
Orthofix Medical Inc. (OFIX)
Dror Ortho-Design, Inc. (DROR)
FUJIFILM Holdings Corporation (FUJIF)
Theradiag S.A. (ALTER.PA)
Business
Cerus Corporation (Nasdaq: CERS), headquartered in Concord, California and founded in 1991, develops and commercializes the INTERCEPT Blood System, a pathogen reduction technology designed to safeguard platelet, plasma and cryoprecipitate blood components against bacterial contamination, viruses and other pathogens for transfusion to patients; the system employs a photochemical treatment process using amotosalen and ultraviolet A light illumination, followed by the use of the INTERCEPT processing sets and accessories including platelet and plasma containers, illumination devices, and transfer sets. Core products include the INTERCEPT Blood System for platelets and plasma, approved by the FDA and bearing CE mark in Europe and available in the United States, Europe, the Middle East, the Commonwealth of Independent States, Latin America and other international markets through direct sales forces and distributors; the INTERCEPT Blood System for Cryoprecipitation, which produces Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex or IFC) approved in the US for treating bleeding associated with fibrinogen deficiency including massive hemorrhage; and the INTERCEPT Blood System for red blood cells, currently in late-stage clinical development. The company also offers implementation, training, technical support and maintenance services to facilitate adoption by blood centers and hospitals; it targets healthcare providers such as blood collection organizations, hospitals and ultimately patients reliant on safe transfusions within the biotechnology and medical devices sectors focused on transfusion medicine and blood safety. Recent developments include record third quarter 2025 results with raised full-year 2025 product revenue guidance driven by strong North American platelet growth, IFC business expansion and increased production capacity; an extended supply agreement with Porex Corporation effective January 1, 2025 through December 31, 2027 for platelet wafers and plasma disks ensuring supply chain stability with fixed pricing for the first two years; plans to launch an LED illuminator in Europe in 2025 and the US in 2026; a $248 million BARDA contract to advance the INTERCEPT red blood cell program; and a formal recommendation from the German National Blood Advisory Committee for enhancing platelet transfusion safety using pathogen reduction.

Company News

APIChatGPT

  • defenseworld.net

    Amova Asset Management Americas Inc. Sells 193,353 Shares of Cerus Corporation $CERS

  • businesswire.com

    Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026

  • businesswire.com

    Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress

  • businesswire.com

    Cerus Corporation Closes New Debt Facility of Up to $110 Million

  • businesswire.com

    Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena

  • seekingalpha.com

    Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

  • seekingalpha.com

    Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

  • businesswire.com

    Cerus Corporation Announces First Quarter 2026 Financial Results

  • businesswire.com

    Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

  • defenseworld.net

    Critical Analysis: Akanda (NASDAQ:AKAN) and Cerus (NASDAQ:CERS)

  • businesswire.com

    Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

  • defenseworld.net

    Kevin Dennis Green Sells 127,544 Shares of Cerus (NASDAQ:CERS) Stock

  • defenseworld.net

    Vivek Jayaraman Sells 165,200 Shares of Cerus (NASDAQ:CERS) Stock

  • defenseworld.net

    Chrystal Jensen Sells 113,008 Shares of Cerus (NASDAQ:CERS) Stock

  • businesswire.com

    Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

  • defenseworld.net

    Cerus Details INTERCEPT Growth Plan, BCA Deal Upside and 2026 RBC Milestones at TD Cowen Conference

  • seekingalpha.com

    Cerus's Record 2025 Sets It Up For Another Leg Higher

  • seekingalpha.com

    Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

  • businesswire.com

    Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

  • defenseworld.net

    Cerus (NASDAQ:CERS) Stock Price Crosses Above 200-Day Moving Average – Should You Sell?